246 related articles for article (PubMed ID: 28429453)
1. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.
Maser T; Rich M; Hayes D; Zhao P; Nagulapally AB; Bond J; Saulnier Sholler G
Cancer Med; 2017 Jun; 6(6):1341-1352. PubMed ID: 28429453
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Forester SC; Lambert JD
Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
[TBL] [Abstract][Full Text] [Related]
3. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
Detrait ER; Carr GV; Weinberger DR; Lamberty Y
Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
[TBL] [Abstract][Full Text] [Related]
4. Genotype-Dependent Effects of COMT Inhibition on Cognitive Function in a Highly Specific, Novel Mouse Model of Altered COMT Activity.
Barkus C; Korn C; Stumpenhorst K; Laatikainen LM; Ballard D; Lee S; Sharp T; Harrison PJ; Bannerman DM; Weinberger DR; Chen J; Tunbridge EM
Neuropsychopharmacology; 2016 Dec; 41(13):3060-3069. PubMed ID: 27388330
[TBL] [Abstract][Full Text] [Related]
5. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Korlipara LV; Cooper JM; Schapira AH
Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
[TBL] [Abstract][Full Text] [Related]
6. Catechol-O-Methyltransferase inhibition and alcohol use disorder: Evaluating the efficacy of tolcapone in ethanol-dependent rats.
Doyle MR; Dirik S; Martinez AR; Hughes TE; Iyer MR; Sneddon EA; Seo H; Cohen SM; de Guglielmo G
Neuropharmacology; 2024 Jan; 242():109770. PubMed ID: 37858886
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.
Lee TT; Chana G; Gorry PR; Ellett A; Bousman CA; Churchill MJ; Gray LR; Everall IP
J Neurovirol; 2015 Oct; 21(5):535-43. PubMed ID: 26037113
[TBL] [Abstract][Full Text] [Related]
8. Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study.
Ashare RL; Wileyto EP; Ruparel K; Goelz PM; Hopson RD; Valdez JN; Gur RC; Loughead J; Lerman C
Drug Alcohol Depend; 2013 Dec; 133(3):852-6. PubMed ID: 24095246
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.
Pinheiro SD; Serrão MP; Silva T; Borges F; Soares-da-Silva P
Eur J Pharmacol; 2019 Mar; 847():53-60. PubMed ID: 30685433
[TBL] [Abstract][Full Text] [Related]
10. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
11. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions.
Laatikainen LM; Sharp T; Harrison PJ; Tunbridge EM
PLoS One; 2013; 8(4):e61839. PubMed ID: 23613951
[TBL] [Abstract][Full Text] [Related]
12. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Borges N
Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
[TBL] [Abstract][Full Text] [Related]
13. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.
Boehn SN; Spahn S; Neudecker S; Keppler A; Bihoreau MT; Kränzlin B; Pandey P; Hoffmann SC; Li L; Torres VE; Gröne HJ; Gretz N
Nephrol Dial Transplant; 2013 Aug; 28(8):2045-58. PubMed ID: 23543593
[TBL] [Abstract][Full Text] [Related]
15. Differential COMT expression and behavioral effects of COMT inhibition in male and female Wistar and alcohol preferring rats.
McCane AM; DeLory MJ; Timm MM; Janetsian-Fritz SS; Lapish CC; Czachowski CL
Alcohol; 2018 Mar; 67():15-22. PubMed ID: 29310047
[TBL] [Abstract][Full Text] [Related]
16. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.
Sant'Anna R; Gallego P; Robinson LZ; Pereira-Henriques A; Ferreira N; Pinheiro F; Esperante S; Pallares I; Huertas O; Almeida MR; Reixach N; Insa R; Velazquez-Campoy A; Reverter D; Reig N; Ventura S
Nat Commun; 2016 Feb; 7():10787. PubMed ID: 26902880
[TBL] [Abstract][Full Text] [Related]
17. Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition.
Laatikainen LM; Sharp T; Bannerman DM; Harrison PJ; Tunbridge EM
J Psychopharmacol; 2012 Dec; 26(12):1561-8. PubMed ID: 22815336
[TBL] [Abstract][Full Text] [Related]
18. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
[TBL] [Abstract][Full Text] [Related]
19. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.
Robinson RG; Smith SM; Wolkenberg SE; Kandebo M; Yao L; Gibson CR; Harrison ST; Polsky-Fisher S; Barrow JC; Manley PJ; Mulhearn JJ; Nanda KK; Schubert JW; Trotter BW; Zhao Z; Sanders JM; Smith RF; McLoughlin D; Sharma S; Hall DL; Walker TL; Kershner JL; Bhandari N; Hutson PH; Sachs NA
ACS Chem Neurosci; 2012 Feb; 3(2):129-40. PubMed ID: 22860182
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
